[Clinical outcomes of allograft Cages in transforaminal lumbar interbody fusion].
To explore the fusion effect of allograft Cages on transforaminal lumbar interbody fusion (TLIF). The clinical data of 30 patients (38 vertebral segments) who underwent TLIF with allograft interbody fusion Cages between January 2015 and January 2017 were retrospectively analysed. There were 25 males and 5 females with an average age of 56.9 years (range, 44-72 years). The lesions included 20 cases of lumbar disc herniation, 7 cases of lumbar spondylolisthesis, and 3 cases of lumbar spinal stenosis. The operation section included 4 cases of L 3, 4, 13 cases of L 4, 5, 5 cases of L 5, S 1, 6 cases of L 4, 5-L 5, S 1, and 2 cases of L 3, 4-L 4, 5. The disease duration was 6-36 months (mean, 12 months). The clinical effectiveness was evaluated by visual analogue scale (VAS) score, Oswestry disability index (ODI), and Japanese Orthopaedic Association (JOA) score at preoperation, 3 months and 6 months after operation, and last follow-up. The fusion rate was evaluated by anteroposterior and lateral X-ray films and CT three-dimensional reconstruction at 3 and 6 months after operation. The intervertebral space height was measured on anteroposterior and lateral X-ray films at preoperation, 3 days, 3 months, and 6 months after operation. The operation time was 2.1-4.3 hours (mean, 3.1 hours), and the intraoperative blood loss was 150-820 mL (mean, 407.5 mL). The follow-up time was 8-25 months (mean, 16.4 months). One Cage split at 6 months after operation without Cage movement and neurologic symptoms; none of the other patients had Cage prolapse, displacement, and fragmentation. No local or systemic allergy or infection signs was found in all patients. No nerve compression or symptoms was observed during the follow-up. The postoperative VAS score, ODI score, and JOA score improved significantly when compared with preoperative scores ( P<0.05); and the scores at 6 months and at last follow-up were significantly improved when compared with those at 3 months after operation ( P<0.05); but no significant difference was found between at 6 months and at last follow-up ( P>0.05). The fusion rate was 55.3% (21/38), 92.1% (35/38), and 100% (38/38) at 3 months, 6 months, and last follow-up postoperatively. The intervertebral space height was increased significantly at 3 days, 3 months, 6 months, and last follow-up postoperatively when compared with preoperative ones ( P<0.05); and the loss of intervertebral space height was significant at last follow-up when compared with postoperative at 3 days ( P<0.05). The allograft interbody fusion Cage contributes to the spine interbody fusion by providing an earlier stability and higher fusion rate.